Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pathologic Processes 1Pancreatic Neoplasms 1Neoplastic Processes 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1

Interventions

Sorafenib 5lenvatinib 3sintilimab 2pembrolizumab 2halofantrine 2camrelizumab 2atezolizumab 2Immunotherapy 2Blood Specimen Collection 2Bevacizumab 2Antibodies 2trifluridine tipiracil drug combination 1trametinib 1toripalimab 1titanium silicide 1tislelizumab 1linifanib 1genexol-PM 1gadolinium ethoxybenzyl DTPA 1fluorocholine 1fisogatinib 1ficlatuzumab 1durvalumab 1bavituximab 1avelumab 1User-Centered Design 1Sunitinib 1Sufentanil 1Standard of Care 1Shadowing Technique, Histology 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Diseases × ficlatuzumab × Gastrointestinal × Clear all
NCT00969410 2012-04-12

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
19 enrolled
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡